WO2017084495A1 - Pd-l1抗体、其抗原结合片段及其医药用途 - Google Patents
Pd-l1抗体、其抗原结合片段及其医药用途 Download PDFInfo
- Publication number
- WO2017084495A1 WO2017084495A1 PCT/CN2016/104320 CN2016104320W WO2017084495A1 WO 2017084495 A1 WO2017084495 A1 WO 2017084495A1 CN 2016104320 W CN2016104320 W CN 2016104320W WO 2017084495 A1 WO2017084495 A1 WO 2017084495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- sequence
- heavy chain
- seq
- antigen
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
待测抗体 | 干扰素-γ释放EC50(ng/ml) |
MPDL3280A | 72.1 |
HRP00052 | 18.7 |
HRP00049 | 34 |
待检抗体 | T细胞增殖EC50(ng/ml) | IFN-γEC50(ng/ml) |
HRP00052 | 9.8 | 19.6 |
HRP00049 | 112 | 45.5 |
MPDL3280A | 1464 | 353 |
Claims (25)
- 根据权利要求1所述的PD-L1抗体或其抗原结合片段,其包含选自SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:12,SEQ ID NO:16,SEQ ID NO:17和SEQ ID NO:18的抗体重链可变区HCDR序列或其突变序列。
- 根据权利要求1所述的PD-L1抗体或其抗原结合片段,其包含选自SEQ ID NO:13,SEQ ID NO:14,SEQ ID NO:15,SEQ ID NO:19,SEQ ID NO:20,SEQ ID NO:21的抗体轻链可变区LCDR序列或其突变序列。
- 根据权利要求1~3任一项所述的PD-L1抗体或其抗原结合片段,其中抗体轻链可变区进一步包含鼠源κ链或鼠源κ链变体的轻链FR区、或者鼠源λ链或鼠源λ链变体的轻链FR区;其中抗体重链可变区进一步包含鼠源IgG1或其变体的重链FR区、或IgG2或其变体的重链FR区、或IgG3或其变体的重链FR区。
- 根据权利要求4所述的PD-L1抗体或其抗原结合片段,其中所述的包含鼠源FR区的抗体重链可变区选自SEQ ID NO:6、8或其突变序列,所述的包含鼠源FR区的抗体轻链可变区选自SEQ ID NO:7、9或其突变序列。
- 根据权利要求4所述的PD-L1抗体或其抗原结合片段,其中抗体重链进一步包含鼠源κ链或其变体的轻链恒定区、或者鼠源λ链或其变体的轻链恒定区;其中抗体轻链进一步包含鼠源IgG1或其变体的重链恒定区、或IgG2或其变体的重链恒定区、或IgG3或其变体的重链恒定区。
- 根据权利要求1-5任一项所述的PD-L1抗体或其抗原结合片段,其中所述的抗体或其抗原结合片段为嵌合抗体。
- 根据权利要求1-3任一项所述的PD-L1抗体或其抗原结合片段,其中所述的抗体或其抗原结合片段为人源化抗体或其片段。
- 根据权利要求8所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体为人源化抗体9-2或人源化抗体24D5,所述人源化抗体重链可变区上的重链FR区序列来源于人种系重链,其中:人源化抗体9-2重链可变区上的重链FR区序列来源于人种系重链IGHV4-30-4*01和hjh2的组合序列;其包含人种系重链IGHV4-30-4*01的FR1、FR2、FR3区和hjh2的FR4区;或人源化抗体24D5重链可变区上的重链FR区序列来源于人种系重链IGHV1-46*01和hjh6.1的组合序列;其包含人种系重链IGHV1-46*01的FR1、FR2、FR3区和hjh6.1的FR4区。
- 根据权利要求9所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体9-2的重链FR区序列有0-10个氨基酸的回复突变,优选为一个或多个选自W47Y、V71R、G27Y、I48M、V67L、F78Y、S30T、和Q39K的氨基酸回复突变,更优选为选自W47Y和V71R的氨基酸回复突变;其中所述人源化抗体24D5的重链FR区序列有0-10个氨基酸的回复突变,优选为一个或多个选自T74K、R72V、M48I、M70L、R38Q、L83F、V68A、和V79A的氨基酸回复突变。
- 根据权利要求9所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体的重链可变区序列如下:人源化抗体9-2重链可变区序列为SEQ ID NO:22所示的序列或其变体;或人源化抗体24D5重链可变区序列为SEQ ID NO:24所示的序列或其变体。
- 根据权利要求8所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体为人源化抗体9-2或人源化抗体24D5,所述人源化抗体轻链可变区上的轻链FR区序列来源于人种系轻链,其中:人源化抗体9-2轻链可变区上的轻链FR区序列来源于人种系轻链IGKV4-1*01和hjk4.1的组合序列;其包含人种系轻链IGKV4-1*01的FR1、FR2、FR3区和hjk4.1的FR4区;人源化抗体24D5轻链可变区上的轻链FR区序列来源于人种系轻链IGKV7-3*01和hjk2.1的组合序列;其包含人种系轻链IGKV7-3*01的FR1、FR2、FR3区和hjk2.1的FR4区。
- 根据权利要求12所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体9-2的轻链FR区序列有0-10个氨基酸的回复突变,优选为P49S的氨基酸回复突变;其中所述人源化抗体24D5的轻链FR区序列有0-10个氨基酸的回复突变,优选为一个或多个选自Y91F、T22S、和G72E的氨基酸回复突变,或者引入N85E去糖基化突变。
- 根据权利要求12所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体的轻链可变区序列如下:人源化抗体9-2轻链可变区序列为SEQ ID NO:23所示的序列或其变体;或人源化抗体24D5轻链可变区序列为SEQ ID NO:25所示的序列或其变体。
- 根据权利要求8-14任一项所述的PD-L1抗体或其抗原结合片段,其中所述的人源化抗体或其抗原结合片段进行亲和力成熟设计。
- 根据权利要求15所述的PD-L1抗体或其抗原结合片段,其中X1为T,X2为H,X3为H,X4为G,X5为F。
- 根据权利要求15或16所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体为人源化抗体9-2或人源化抗体24D5,其中所述的人源化抗体可变区序列如下:人源化抗体9-2:重链可变区序列为SEQ ID NO:26;轻链可变区序列为SEQ ID NO:27;人源化抗体24D5:重链可变区序列为SEQ ID NO:28,轻链可变区序列为SEQ ID NO:29。
- 根据权利要求17所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体重链进一步包含人源IgG1、IgG2、IgG3或IgG4或其变体的重链恒定区,优选包含人源IgG2或IgG4重链恒定区,更优选包含引入F234A和L235A突变的IgG4重链恒定区;所述人源化抗体轻链进一步包含人源κ、λ链或其变体的恒定区。
- 根据权利要求17所述的PD-L1抗体或其抗原结合片段,其中所述人源化抗体9-2包含重链抗体序列SEQ ID NO:30,和轻链抗体序列SEQ ID NO:32;其中所述人源化抗体24D5包含重链抗体序列SEQ ID NO:34,和轻链抗体序列SEQ ID NO:36。
- 一种药物组合物,其含有治疗有效量的根据权利要求1至19任一项所述的PD-L1抗体或其抗原结合片段,以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
- 一种编码根据权利要求1-19任一项所述的PD-L1抗体或其抗原结合片段的DNA分子。
- 一种含有根据权利要求21所述的DNA分子的表达载体。
- 一种用根据权利要求22所述的表达载体转化的宿主细胞,所述宿主细胞选自细菌、酵母菌和哺乳动物细胞;优选哺乳动物细胞。
- 根据权利要求1至19任一项所述的PD-L1抗体或其抗原结合片段或根据权利要求20所述的药物组合物,在制备用于治疗PD-L1介导的疾病或病症的药物中的用途,其中所述的疾病或病症优选为癌症;更优选为表达PD-L1的癌症;最优选为乳腺癌、肺癌、胃癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;进一步优选为非小细胞肺癌、黑素瘤、膀胱癌和肾癌。
- 一种治疗和预防PD-L1介导的疾病或病症的方法,包括给予所需患者治疗有效量的根据权利要求1至19任一项所述的PD-L1抗体或其抗原结合片段或根据权利要求20所述的药物组合物;其中所述的疾病优选为癌症;更优选为表达PD-L1的癌症;所述的癌症最优选为乳腺癌、肺癌、胃癌、肠癌、肾癌、黑素瘤、非小细胞肺癌、膀胱癌;最优选为非小细胞肺癌、黑素瘤、膀胱癌和肾癌。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3004804A CA3004804A1 (en) | 2015-11-17 | 2016-11-02 | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
CN201680027181.4A CN107614529B (zh) | 2015-11-17 | 2016-11-02 | Pd-l1抗体、其抗原结合片段及其医药用途 |
CN201811509306.4A CN109608544B (zh) | 2015-11-17 | 2016-11-02 | Pd-l1抗体、其抗原结合片段及其医药用途 |
KR1020187016423A KR20180071376A (ko) | 2015-11-17 | 2016-11-02 | Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도 |
JP2018522980A JP6983371B2 (ja) | 2015-11-17 | 2016-11-02 | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
US15/775,598 US10815304B2 (en) | 2015-11-17 | 2016-11-02 | PD-L1 antibody, antigen-binding fragment thereof and medical application thereof |
BR112018009064A BR112018009064A8 (pt) | 2015-11-17 | 2016-11-02 | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo |
MX2018005720A MX2018005720A (es) | 2015-11-17 | 2016-11-02 | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. |
RU2018119165A RU2727914C2 (ru) | 2015-11-17 | 2016-11-02 | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение |
AU2016357901A AU2016357901B2 (en) | 2015-11-17 | 2016-11-02 | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
EP16865672.6A EP3378871A4 (en) | 2015-11-17 | 2016-11-02 | PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF |
HK18106682.0A HK1247213A1 (zh) | 2015-11-17 | 2018-05-23 | Pd-l1抗體、其抗原結合片段及其醫藥用途 |
US16/947,583 US11780923B2 (en) | 2015-11-17 | 2020-08-07 | PD-L1 antibody, antigen-binding fragment thereof and medical application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510788907 | 2015-11-17 | ||
CN201510788907.3 | 2015-11-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/775,598 A-371-Of-International US10815304B2 (en) | 2015-11-17 | 2016-11-02 | PD-L1 antibody, antigen-binding fragment thereof and medical application thereof |
US16/947,583 Division US11780923B2 (en) | 2015-11-17 | 2020-08-07 | PD-L1 antibody, antigen-binding fragment thereof and medical application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017084495A1 true WO2017084495A1 (zh) | 2017-05-26 |
Family
ID=58717319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/104320 WO2017084495A1 (zh) | 2015-11-17 | 2016-11-02 | Pd-l1抗体、其抗原结合片段及其医药用途 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10815304B2 (zh) |
EP (1) | EP3378871A4 (zh) |
JP (1) | JP6983371B2 (zh) |
KR (1) | KR20180071376A (zh) |
CN (2) | CN109608544B (zh) |
AU (1) | AU2016357901B2 (zh) |
BR (1) | BR112018009064A8 (zh) |
CA (1) | CA3004804A1 (zh) |
HK (1) | HK1247213A1 (zh) |
MX (1) | MX2018005720A (zh) |
RU (1) | RU2727914C2 (zh) |
TW (1) | TWI718206B (zh) |
WO (1) | WO2017084495A1 (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018210230A1 (zh) * | 2017-05-16 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种pd-l1抗体药物组合物及其用途 |
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
WO2019129211A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019137397A1 (zh) | 2018-01-10 | 2019-07-18 | 江苏恒瑞医药股份有限公司 | Pd-l1抗体、其抗原结合片段及医药用途 |
WO2020094122A1 (zh) | 2018-11-09 | 2020-05-14 | 江苏恒瑞医药股份有限公司 | 一种TGF-β受体融合蛋白药物组合物及其用途 |
WO2020119758A1 (zh) | 2018-12-13 | 2020-06-18 | 江苏恒瑞医药股份有限公司 | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 |
WO2020177733A1 (zh) | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
WO2020249071A1 (en) * | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
WO2021063349A1 (zh) | 2019-09-30 | 2021-04-08 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
WO2022048616A1 (zh) * | 2020-09-04 | 2022-03-10 | 江苏恒瑞医药股份有限公司 | SIRPγ变体及其融合蛋白 |
RU2778085C2 (ru) * | 2018-01-10 | 2022-08-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Антитело к pd-l1, его антигенсвязывающий фрагмент и их фармацевтическое применение |
WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11795206B2 (en) * | 2018-06-24 | 2023-10-24 | Yunbiao Lu | Specific bifunctional BY-001 (active composition of homomultimer of chimeric protein pd-L1 / fc-gamma1) down regulates the activation of human immune cells and the use thereof |
CN112543637B (zh) * | 2018-10-25 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 |
WO2020146423A1 (en) * | 2019-01-07 | 2020-07-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
JP7212990B2 (ja) | 2019-04-26 | 2023-01-26 | アイ-エムエービー バイオファーマ ユーエス リミテッド | ヒトpd‐l1抗体 |
CN112125975B (zh) * | 2019-06-25 | 2024-03-01 | 上海翰森生物医药科技有限公司 | Pd-l1和cd47双特异性融合蛋白及其医药用途 |
WO2021013142A1 (zh) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |
BR112021016512A2 (pt) * | 2019-08-29 | 2022-03-15 | Remegen Co Ltd | Anticorpo anti pd-l1 e uso do mesmo |
CN110478472B (zh) * | 2019-09-29 | 2020-08-28 | 北京鼎成肽源生物技术有限公司 | Pd-1封闭剂及其应用 |
CN112759647B (zh) * | 2019-10-21 | 2024-03-26 | 上海宏成药业有限公司 | 一种抗pd-l1的抗体及其制药用途 |
CN113637075B (zh) * | 2020-04-27 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 双特异性抗原结合分子及其医药用途 |
CN113773401B (zh) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和pd-l1的重组融合蛋白及其制备和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
WO2014055897A2 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
WO2014151006A2 (en) * | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP1910550A4 (en) * | 2005-07-21 | 2009-11-04 | Abbott Lab | MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS |
AU2009256250B2 (en) * | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
PE20120341A1 (es) * | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
KR101573109B1 (ko) * | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
US20120034224A1 (en) * | 2010-08-03 | 2012-02-09 | National Cheng Kung University | Treating Rheumatoid Arthritis with Anti-IL-19 Antibody |
MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
CA2833636A1 (en) * | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
CN115093480A (zh) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
ES2848052T3 (es) | 2012-08-03 | 2021-08-05 | Dana Farber Cancer Inst Inc | Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso |
AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EP3003282A1 (en) | 2013-06-03 | 2016-04-13 | Novartis AG | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
MY175472A (en) | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
LT3097122T (lt) * | 2014-01-24 | 2020-07-27 | Ngm Biopharmaceuticals, Inc. | Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai |
MX2019013751A (es) * | 2017-05-16 | 2020-01-15 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpos del ligando 1 de muerte programada y su uso. |
MX2020007406A (es) * | 2018-01-10 | 2020-09-14 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. |
KR20210137477A (ko) * | 2019-03-06 | 2021-11-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 이중기능성 융합 단백질 및 그것의 제약학적 용도 |
KR20220045019A (ko) * | 2019-08-15 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 면역자극성 다량체 결합 분자 |
-
2016
- 2016-11-02 JP JP2018522980A patent/JP6983371B2/ja active Active
- 2016-11-02 CA CA3004804A patent/CA3004804A1/en active Pending
- 2016-11-02 CN CN201811509306.4A patent/CN109608544B/zh active Active
- 2016-11-02 MX MX2018005720A patent/MX2018005720A/es unknown
- 2016-11-02 KR KR1020187016423A patent/KR20180071376A/ko not_active Application Discontinuation
- 2016-11-02 AU AU2016357901A patent/AU2016357901B2/en active Active
- 2016-11-02 CN CN201680027181.4A patent/CN107614529B/zh active Active
- 2016-11-02 US US15/775,598 patent/US10815304B2/en active Active
- 2016-11-02 BR BR112018009064A patent/BR112018009064A8/pt active Search and Examination
- 2016-11-02 WO PCT/CN2016/104320 patent/WO2017084495A1/zh active Application Filing
- 2016-11-02 EP EP16865672.6A patent/EP3378871A4/en active Pending
- 2016-11-02 RU RU2018119165A patent/RU2727914C2/ru active
- 2016-11-16 TW TW105137421A patent/TWI718206B/zh active
-
2018
- 2018-05-23 HK HK18106682.0A patent/HK1247213A1/zh unknown
-
2020
- 2020-08-07 US US16/947,583 patent/US11780923B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
WO2014055897A2 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
WO2014151006A2 (en) * | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
US11174316B2 (en) | 2015-03-13 | 2021-11-16 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US10669339B2 (en) | 2015-03-13 | 2020-06-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US11654194B2 (en) | 2017-05-16 | 2023-05-23 | Jiangsu Hengrui Medicine Co., Ltd. | PD-L1 antibody pharmaceutical composition and use thereof |
WO2018210230A1 (zh) * | 2017-05-16 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种pd-l1抗体药物组合物及其用途 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
JP7383617B2 (ja) | 2017-12-28 | 2023-11-20 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Pd-l1に対する抗体及びそのバリアント |
CN111542543A (zh) * | 2017-12-28 | 2020-08-14 | 南京传奇生物科技有限公司 | 针对pd-l1的抗体及其变体 |
CN111542543B (zh) * | 2017-12-28 | 2023-12-22 | 南京传奇生物科技有限公司 | 针对pd-l1的抗体及其变体 |
JP2021508707A (ja) * | 2017-12-28 | 2021-03-11 | ナンジン レジェンド バイオテック カンパニー,リミテッドNanjing Legend Biotech Co.,Ltd. | Pd−l1に対する抗体及びそのバリアント |
WO2019129211A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019137397A1 (zh) | 2018-01-10 | 2019-07-18 | 江苏恒瑞医药股份有限公司 | Pd-l1抗体、其抗原结合片段及医药用途 |
CN111278861B (zh) * | 2018-01-10 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | Pd-l1抗体、其抗原结合片段及医药用途 |
CN111278861A (zh) * | 2018-01-10 | 2020-06-12 | 江苏恒瑞医药股份有限公司 | Pd-l1抗体、其抗原结合片段及医药用途 |
US11359021B2 (en) | 2018-01-10 | 2022-06-14 | Jiangsu Hengrui Medicine Co., Ltd. | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
RU2778085C2 (ru) * | 2018-01-10 | 2022-08-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Антитело к pd-l1, его антигенсвязывающий фрагмент и их фармацевтическое применение |
JP2021510078A (ja) * | 2018-01-10 | 2021-04-15 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | Pd−l1抗体、その抗原結合フラグメント、及びその製薬学的使用 |
CN112512550A (zh) * | 2018-11-09 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | 一种TGF-β受体融合蛋白药物组合物及其用途 |
WO2020094122A1 (zh) | 2018-11-09 | 2020-05-14 | 江苏恒瑞医药股份有限公司 | 一种TGF-β受体融合蛋白药物组合物及其用途 |
JP7436477B2 (ja) | 2018-11-09 | 2024-02-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | TGF-β受容体融合タンパク質医薬組成物およびその使用 |
CN112969718A (zh) * | 2018-12-13 | 2021-06-15 | 江苏恒瑞医药股份有限公司 | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 |
WO2020119758A1 (zh) | 2018-12-13 | 2020-06-18 | 江苏恒瑞医药股份有限公司 | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 |
EP3896089A4 (en) * | 2018-12-13 | 2022-09-07 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF IL-15 PROTEIN COMPLEXES IN CONJUNCTION WITH PD-L1 ANTIBODIES FOR THE TREATMENT OF TUMOR DISEASES |
WO2020177733A1 (zh) | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
EP3936526A4 (en) * | 2019-03-06 | 2023-03-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE |
WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
CN114008080B (zh) * | 2019-06-12 | 2023-06-09 | 南京金斯瑞生物科技有限公司 | 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法 |
WO2020249071A1 (en) * | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
CN114008080A (zh) * | 2019-06-12 | 2022-02-01 | 南京金斯瑞生物科技有限公司 | 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法 |
WO2021063349A1 (zh) | 2019-09-30 | 2021-04-08 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
WO2022048616A1 (zh) * | 2020-09-04 | 2022-03-10 | 江苏恒瑞医药股份有限公司 | SIRPγ变体及其融合蛋白 |
WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Also Published As
Publication number | Publication date |
---|---|
US10815304B2 (en) | 2020-10-27 |
CN109608544B (zh) | 2022-09-16 |
BR112018009064A2 (zh) | 2018-10-30 |
RU2727914C2 (ru) | 2020-07-24 |
US20180334504A1 (en) | 2018-11-22 |
EP3378871A1 (en) | 2018-09-26 |
RU2018119165A (ru) | 2019-12-19 |
HK1247213A1 (zh) | 2018-09-21 |
AU2016357901B2 (en) | 2023-05-25 |
AU2016357901A1 (en) | 2018-05-24 |
CA3004804A1 (en) | 2017-05-26 |
CN109608544A (zh) | 2019-04-12 |
MX2018005720A (es) | 2018-11-09 |
JP6983371B2 (ja) | 2021-12-17 |
BR112018009064A8 (pt) | 2019-02-26 |
CN107614529B (zh) | 2019-11-12 |
TWI718206B (zh) | 2021-02-11 |
US11780923B2 (en) | 2023-10-10 |
KR20180071376A (ko) | 2018-06-27 |
RU2018119165A3 (zh) | 2020-02-14 |
US20200399375A1 (en) | 2020-12-24 |
JP2018536401A (ja) | 2018-12-13 |
CN107614529A (zh) | 2018-01-19 |
EP3378871A4 (en) | 2019-08-07 |
TW201718657A (zh) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11780923B2 (en) | PD-L1 antibody, antigen-binding fragment thereof and medical application thereof | |
US11365255B2 (en) | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
WO2018095428A1 (zh) | Cd47抗体、其抗原结合片段及其医药用途 | |
JP7393337B2 (ja) | 抗b7-h4抗体、その抗原結合断片及びその医薬用途 | |
US11525005B2 (en) | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof | |
US20210363266A1 (en) | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof | |
CN112585165A (zh) | 优化的抗tl1a抗体 | |
JP2022509156A (ja) | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 | |
RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16865672 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/005720 Country of ref document: MX Ref document number: 2018522980 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3004804 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15775598 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018009064 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016357901 Country of ref document: AU Date of ref document: 20161102 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187016423 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018119165 Country of ref document: RU Ref document number: 2016865672 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112018009064 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180504 |